A5080893464- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Mechanisms and Therapy
- Liver Disease Diagnosis and Treatment
- Pancreatic and Hepatic Oncology Research
- Peptidase Inhibition and Analysis
- Hepatitis B Virus Studies
- Cancer, Lipids, and Metabolism
- Renal cell carcinoma treatment
- Hepatitis C virus research
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Research Studies
- Parasites and Host Interactions
- Colorectal and Anal Carcinomas
- Nutrition and Health in Aging
- Advanced Steganography and Watermarking Techniques
- Polymer composites and self-healing
- Allergic Rhinitis and Sensitization
- Advanced X-ray and CT Imaging
- interferon and immune responses
- GDF15 and Related Biomarkers
- Liver Disease and Transplantation
- Lung Cancer Treatments and Mutations
- Chaos-based Image/Signal Encryption
- Bladder and Urothelial Cancer Treatments
Wenzhou Medical University
2021-2024
Second Military Medical University
2021-2024
Eastern Hepatobiliary Surgery Hospital
2021-2024
First Affiliated Hospital of Wenzhou Medical University
2021-2023
Northeastern University
2006
Transarterial chemoembolization (TACE) combined with a PD-1 inhibitor and TACE lenvatinib have recently been reported as promising treatments to improve the prognosis of hepatocellular carcinoma (HCC) patients. This study aims compare efficacy these two treatments.A retrospective was conducted, patients were recruited from centers in China. Progression-free survival (PFS) overall (OS) compared, objective response rate (ORR) disease control (DCR) evaluated according modified Response...
Abstract Background There is no consensus on the optimal regimen for unresectable recurrent hepatocellular carcinoma (HCC), so this retrospective study aimed to evaluate efficacy and safety of transarterial chemoembolization (TACE) combined with lenvatinib PD‐1 inhibitors (T‐L‐P) versus TACE (T‐L) or alone. Method Data were collected from 204 patients HCC who received T‐L‐P, T‐L, alone at three medical centers January, 2019 December, 2020 analysis. The survival outcomes, tumor response,...
Background and aims The efficacy safety of systemic atezolizumab bevacizumab (atezo/bev) in treatment patients with unresectable hepatocellular carcinoma (HCC) have been demonstrated. However, the this HCC extrahepatic portal vein tumor thrombus (ePVTT) is not satisfactory. This study aimed to combining intensity-modulated radiotherapy (IMRT) atezo/bev these patients. Methods multicenter prospective included ePVTT treated IMRT combined from March September 2021 three centers China. outcomes...
Locoregional treatment, such as TACE, in combination with immunotherapy may elicit a synergistic anticancer effect. However, TACE combined atezolizumab plus bevacizumab (atezo/bev) has not been investigated for patients intermediate stage (BCLC B) HCC beyond the up-to-seven criteria. This study aims to evaluate efficacy and safety of this treatment strategy intermediate-stage large or multinodular tumors exceeding multicenter retrospective included criteria treated atezo/bev from five...
Combining transarterial chemoembolization (TACE) with systemic therapy has shown significant efficacy for intermediate-stage hepatocellular carcinoma (HCC) patients. This study aimed to validate the therapeutic of TACE combined atezolizumab and bevacizumab (TACE + Atez/Bev) compared alone.
Patients with intermediate-stage hepatocellular carcinoma (HCC) who are refractory to transarterial chemoembolization (TACE) have a poor prognosis. This study aimed explore whether stereotactic body radiation therapy (SBRT) combined PD-1 inhibitors could improve the clinical outcomes of such patients.This retrospective cohort included patients HCC were diagnosed TACE refractoriness between January 2019 and December 2020 in Eastern Hepatobiliary Surgery Hospital First Affiliated Wenzhou...
This study aimed to assess the efficacy and safety of a triple therapy that comprises transarterial chemoembolization (TACE), antiangiogenic-targeted therapy, programmed death-1 (PD-1) inhibitors in real-world cohort patients with unresectable hepatocellular carcinoma (HCC) portal vein tumor thrombus (PVTT).Consecutive treated TACE combined antiangiogenic PD-1 at Eastern Hepatobiliary Surgery Hospital between June 2019 May 2021 were enrolled. The baseline characteristics treatment course...
Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of hepatocellular carcinoma (HCC). However, long-term survival outcomes and response HCC patients undergoing immunotherapy is unpredictable. The study aimed to evaluate role alpha-fetoprotein (AFP) combined with neutrophil-to-lymphocyte ratio (NLR) predict prognosis receiving ICIs.Patients unresectable who received ICI were included. score was developed from a retrospective cohort at Eastern Hepatobiliary Surgery Hospital...
Abstract Background Early and late recurrence of hepatocellular carcinoma (HCC) have different clinical outcomes, especially for those accompanied by microvascular invasion (MVI), but the definition early remains controversial. Therefore, a reasonable identification time HCC is urgently needed. Methods Resected patients were enrolled divided into two cohorts, one another verification accuracy point. Univariable multivariable Cox regression analyses adopted to identify prognostic factors...
Anti-programmed cell death ligand 1/vascular endothelial growth factor inhibition, coupled with chemotherapy, may potentiate antitumor immunity leading to enhanced clinical benefit, but it has not been investigated in advanced biliary tract cancer (BTC).We the efficacy and safety of atezolizumab, bevacizumab, gemcitabine plus oxaliplatin (GEMOX) BTC explore potential biomarkers related response.Multicenter, single-arm, retrospective study.Advanced patients, who received a triple combination...
Metastasis is the main cause of colorectal cancer (CRC)-related death, and 5-year relative survival rate for CRC patients with distant metastasis only 14%. X-linked inhibitor apoptosis (XIAP)-associated factor 1 (XAF1) a zinc-rich protein belonging to interferon (IFN)-induced gene family. Here, we report metastasis-promoting role XAF1 in by acting as novel adaptor valosin-containing (VCP). facilitates VCP-mediated deubiquitination E3 ligase RING finger 114 (RNF114), which promotes K48-linked...
Background Immune checkpoint inhibitor (ICI), coupled with systemic chemotherapy, may enhance the clinical benefit of cancer by potentiating antitumor immunity, but its efficacy and safety are not clear in advanced intrahepatic cholangiocarcinoma (ICC). This study aims to assess camrelizumab plus gemcitabine oxaliplatin (GEMOX) for treatment ICC real world. Methods Advanced patients receiving at least one session GEMOX combination from March 2020 February 2022 two high-volume centers were...
The use of Anti-PD-1 therapy has yielded promising outcomes in hepatocellular carcinoma (HCC). However, limited research been conducted on the overall survival (OS) patients with varying tumor responses and treatment duration.This retrospective study analyzed HCC who received sintilimab between January 2019 December 2020 at four centers China. evaluation progression was based Response Evaluation Criteria Solid Tumors version 1.1. investigated correlation response OS, impact drug OS following...
The therapeutic effect of transcatheter arterial chemoembolization (TACE) is limited for patients with hepatocellular carcinoma (HCC). Herein, we designed an open-label, single-arm phase II clinical trial to investigate the efficacy and safety TACE combined atezolizumab plus bevacizumab Barcelona Clinic Liver Cancer (BCLC) stage-B HCC. Patients will initially receive TACE. Atezolizumab be initiated 2-14 days after first session. repeated on demand. primary endpoint objective response rate....
子宫内膜癌是女性生殖系统三大恶性肿瘤之一。在欧美国家，子宫内膜癌的发病率已居女性生殖系统恶性肿瘤的首位，在我国也呈现上升趋势。如何在人群中筛选出子宫内膜癌前病变及早期子宫内膜癌，提高子宫内膜癌的筛查效率，实现子宫内膜癌的早发现、早诊断、早治疗，已势在必行。本建议根据我国子宫内膜癌的诊治经验及筛查现状，结合国际筛查指南及国内外文献，经过中国医师协会妇产科学分会各位专家多次讨论，对于子宫内膜癌的筛查及早期诊断达成了新的规范建议。.
Background Microvascular invasion (MVI) is a significant risk factor affecting survival outcomes of patients after R0 liver resection (LR) for hepatocellular carcinoma (HCC). However, whether the existing staging systems can distinguish prognosis with MVI and prognostic value in different subtypes remains to be clarified. Methods A dual-center retrospective data set 1,198 HCC who underwent LR was included study between 2014 2016. Baseline characteristics information were collected....